Skip to main content

Connective tissue diseases

Clinical trials

23-08-2022 | Systemic lupus erythematosus | News

LUPIL-2: Aldesleukin warrants further investigation for SLE

Phase 2 trial results suggest that low-dose interleukin-2 therapy with aldesleukin may represent a promising add-on treatment option for systemic lupus erythematosus.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Get ready for ACR Convergence 2020

ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Kidneys

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

Emerging therapies for lupus nephritis

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

12-05-2018 | Systemic lupus erythematosus | Article

Nutritional intervention in patients with juvenile systemic lupus erythematosus: Protective effect against the increase in fat mass

Abad TO et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4031-3

New trials in lupus and where are we going

New trials in lupus and where are we going

In this article, the authors review progress in the field of clinical trials for systemic lupus erythematosus [read more].
Thanou A, Merrill JT. Curr Rheumatol Rep 2018; 20: 34. doi: 10.1007/s11926-018-0745-1

Lupus word cloud

03-05-2018 | Systemic lupus erythematosus | Review | Article

New trials in lupus and where are we going

In this article, the authors review progress in the field of clinical trials for systemic lupus erythematosus.

Thanou A, Merrill JT. Curr Rheumatol Rep 2018; 20: 34. doi: 10.1007/s11926-018-0745-1

24-01-2018 | Pathogenesis | Review | Article

Moving towards a molecular taxonomy of autoimmune rheumatic diseases

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220